Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow CervoMed Inc.

Get SEC filing alerts via email and in your feed for CervoMed Inc.

CRVO

CervoMed Inc.

About CervoMed Inc.

CervoMed Inc. is a clinical-stage biotechnology company developing treatments for age-related neurological disorders. Its lead candidate, neflamapimod, is an oral small molecule targeting neuroinflammation and synaptic dysfunction in diseases like dementia with Lewy bodies (DLB), FTD, and stroke recovery. The company focuses on early intervention, leveraging its understanding of neurodegenerative mechanisms to slow or reverse disease progression.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from CervoMed Inc.

1
1
CervoMed Inc. CervoMed Reports $7.96 Million Net Loss in Q1 2026, Seeks Additional Financing

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
CervoMed Inc. CervoMed Inc. Reports Fiscal Year 2025 Financial Results and Business Update

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
CervoMed Inc. CervoMed Reports $7.7 Million Net Loss in Q3 2025, Plans Phase 3 Trial for Neflamapimod

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
CervoMed Inc. CervoMed Reports Increased Net Losses and Declining Grant Revenue in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
CervoMed Inc. CervoMed Reports $4.9 Million Net Loss in Q1 2025, Increased R&D Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
CervoMed Inc. CervoMed Inc. Reports $16.3 Million Net Loss for 2024, Driven by Increased R&D Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
CervoMed Inc. CervoMed Reports Significant Net Loss and Increased Grant Revenue in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments